In separate small clinical trials, two treatments showed promise that they could help patients with one of the most dire ...

What is the significance of Path-IO and how could it contribute to clinical care? Immunotherapy has been a transformational ...

Thanks to major scientific breakthroughs, Dr. David Carbone says survival rates have doubled — and in some cases, patients ...

Macrophages, key regulators of tissue health and immune defense, are among the most abundant immune cells in solid tumors. Their role in cancer has been difficult to define because even closely ...

Daryl Pritchard, PhD, discusses the challenges to implementing biomarker testing that would advance precision medicine and ...

In lung cancer, surgical resection remains the primary curative treatment, particularly for early-stage Non-Small Cell Lung Cancer (NSCLC). To augment these ...

The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...

The platform trial will add new arms testing Enhertu in solid tumors with HER2 amplification and gather data on Tafinlar-Mekinist's tissue-agnostic benefit for regular approval.

In combination with atezolizumab, ZEPZELCA has been approved for use in Australia and Singapore as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) in adult patients whose ...

An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center ...

Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors ...